Abstract
The effect of SARS-CoV-2 seropositivity on the immune response to mRNA-based SARS-CoV-2 vaccines has not been well-described. Here we report longitudinal SARS-CoV-2-specific antibody responses pre- and post-vaccination among a cohort of healthcare personnel, with and without prior infection, from a large academic medical center. Our results provide preliminary evidence that prior SARS-CoV-2 infection may prime the response to the first mRNA-based SARS-CoV-2 vaccine dose. These findings could have significant impact on the allocation of mRNA-based vaccines and support the need for future research into the effect of prior infection on magnitude and durability of vaccination response.
Introduction
The impact of prior SARS-CoV-2 infection on antibody response to mRNA-based vaccines has not been well-characterized. Early reports suggest that it may prime the immune response to the first vaccine dose, but these reports did not include longitudinal antibody levels before vaccination.1–3 This information is important as the timing of natural infection in relation to vaccination may impact response. The Centers for Disease Control and Prevention (CDC) recently suggested that individuals with documented immunity might defer vaccination for 90 days to expedite access for those without immunity, but data supporting these guidelines are limited.4 Here, we examined longitudinal SARS-CoV-2 antibody responses among healthcare personnel (HCP) with and without prior infection to examine the impact of natural infection on vaccination response.
Methods
We conducted a longitudinal study of HCP at a large medical center that began enrolling in July 2020.5 Participants provided blood samples every two weeks for the first 12 weeks and monthly thereafter. mRNA-based SARS-CoV-2 vaccinations (Pfizer-BioNTech [BNT162b2] and Moderna [mRNA-1273]) became available to HCP on December 16, 2020. For all pre- and post-vaccination samples, we measured total immunoglobulin antibodies specific to the receptor binding domain of the SARS-CoV-2 spike protein by ELISA with a positive to negative ratio (P/N) cut-off of 2.57 to ensure 99.5% specificity per CDC guidelines.6,7 Exact Wilcoxon rank sum tests were used to compare median P/N between seropositive and seronegative participants and change in P/N for those with paired pre- and post-vaccination measurements.
Results
As of February 2, 2021, the study enrolled 213 HCP with 194 (91%) providing at least one blood sample. One individual was excluded due to co-enrollment in a SARS-CoV-2 treatment trial.Table 1 presents the cohort demographics. Five participants (3%) had antibodies to SARS-CoV-2 at their baseline study visit (prevalent seropositive; Figure 1A). Notably, one demonstrated persistent seropositivity for six months, while another remained seropositive for over three months before reverting to seronegative one month prior to vaccination. Five participants (3%) became seropositive during the study (incident seropositive; Figure 1A); four (80%) reported COVID-19 symptoms at seroconversion.
Most participants (96%, 187/193) received at least one dose of a SARS-CoV-2 mRNA-based vaccine. Antibody measurements after at least one vaccine dose were available for 60% (6/10) of seropositive and 44% (81/183) of seronegative participants. Those who were seropositive at any point developed a two-fold higher antibody response to their first vaccine dose (V1) compared to those who were seronegative (median P/N 13.8 vs. 7.0; p=0.008; Figure 1B). Additionally, the post-V1 antibody levels in seropositive participants were similar to those of seronegative participants after the second vaccine dose (13.8 vs. 13.2; p=0.768). The magnitude of the increase in antibody levels from pre-vaccination to post-V1 was greater for seropositive than seronegative participants (change in P/N 8.6 vs. 5.4, p=0.14).
Discussion
Our findings provide preliminary evidence that prior SARS-CoV-2 infection may prime the primary vaccination response, corroborating recent non-peer-reviewed findings.1–3 Specifically, we observed that the response to one vaccine dose among seropositive individuals was of similar magnitude to that of seronegative individuals to two vaccine doses. Additionally, our results suggest that the magnitude of the increase in antibody levels in response to the first dose of vaccine might be larger for seropositive than seronegative individuals. Future research on the durability of response to the first dose of SARS-CoV-2 vaccine among previously infected individuals, and the impact of time between infection and vaccination, will help guide the allocation of the limited supply of mRNA-based vaccines. As 27 million Americans have been infected with SARS-CoV-2 to date, the potential ability for some individuals to forgo a second vaccination may have substantial impact on vaccination distribution strategies.
Data Availability
The study described in this manuscript is ongoing, and therefore, the data are not yet available to others. Once study follow-up is completed, the data will be made available by request.
Conflicts of Interest
The authors report no conflicts of interest.
Funding/Support
This project was supported by funds from the following sources:
2007 Gillings Gift at the UNC Gillings School of Global Public Health (AEA)
North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill with funding from the North Carolina Coronavirus Relief Fund established and appropriated by the North Carolina General Assembly (EJC, RMB, RA, DRZ)
UNC School of Medicine (RMB)
A generous donation to the UNC School of Medicine by an anonymous donor (RMB)
National Institute of Occupational Safety and Health through Grant Award Number [75D30121P10086 0000HCCK-2021] (AEA, EJC)
National Science Foundation through Grant Award Number NSF 20-4353 (AEA)
National Institutes of Health through Grant Award Number R01 EB0225021 (AEA)
National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001111 supported the use of the REDCap database. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
In addition, EJC is supported by the National Heart, Lung, and Blood Institute through Grant Award Number [5T32HL007106-43], RMB is supported by the National Institute of Allergy and Infectious Diseases through Grant Award Number [5K23AI141764-03], and BES is supported by the University of North Carolina at Chapel Hill Center for AIDS Research (CFAR), an NIH funded program P30 AI050410.
The funding organizations/sponsors were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Acknowledgements
We thank the participants for their willingness to contribute to advancing our understanding of the SARS-CoV-2 epidemic and its impact on healthcare personnel, especially during the early and uncertain months of the pandemic. We also appreciate the hard work of the graduate student assistants from the University of North Carolina Gillings School of Global Public Health (Elle Law, BS, Elyse Miller, BA, and Paul Zivich, MPH) and the phlebomists who contributed to the sample collection, protocols, and day-to-day implementation of the study (these individuals received compensation for their work on the study). We acknowledge Premkumar Lakshmanane, PhD who spearheaded development of the ELISA assay and produced and supplied the necessary antigens for the study through funding from the National Cancer Institute [1U54CA260543]. Finally, we thank Subhashini Sellers, MD, MSc and Meghan Rebuli, PhD (University of North Carolina School of Medicine) and Bailey Fosdick, PhD (Colorado State University Department of Statistics) for their support of this study and its analysis. These contributors did not receive any contribution for their role in the study.